AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38837237 — intervention group
Group type: COMPARATOR
Intervention: Pulsed high-intensity laser
Number of subjects: 1166
Study 38837240 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 8449
Study 38837273 — intervention group
Group type: COMPARATOR
Intervention: G2 (left heart disease)
Number of subjects: 308
Study 38837273 — intervention group
Group type: COMPARATOR
Intervention: G2-3 (combined G2/3 and G3/2)
Number of subjects: 308
Study 38837273 — intervention group
Group type: COMPARATOR
Intervention: G2
Number of subjects: 308
Study 38837273 — intervention group
Group type: COMPARATOR
Intervention: G2 and G2-3
Number of subjects: 308
Study 38837273 — intervention group
Group type: EXPERIMENTAL
Intervention: G3
Number of subjects: 308
Study 38837273 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 308
Study 38837707 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) levels ≤500 ng/ml
Number of subjects: 174
Study 38837707 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) levels ≤200 ng/ml
Number of subjects: 174
Study 38837825 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator therapy (specific medication not mentioned), administered twice daily for 12 weeks.
Number of subjects: 200
Study 38837825 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving placebo treatment for 12 weeks.
Number of subjects: 200
Study 38837864 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-tiered dosing of pantoprazole
Number of subjects: 0
Study 38837864 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg total body weight dosing of pantoprazole
Number of subjects: 0
Study 38837864 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg/kg lean body weight dosing of pantoprazole
Number of subjects: 0
Study 38837864 — intervention group
Group type: EXPERIMENTAL
Intervention: FDA-recommended weight-tiered dosing of pantoprazole
Number of subjects: 0
Study 38837894 — intervention group
Group type: EXPERIMENTAL
Intervention: PIK3CA mutation in exon 20
Number of subjects: 1691
Study 38837894 — intervention group
Group type: EXPERIMENTAL
Intervention: PIK3CA mutation in exon 20 in hormone receptor-positive HER2-positive breast cancer
Number of subjects: 1691
Study 38837894 — intervention group
Group type: EXPERIMENTAL
Intervention: PIK3CA mutation
Number of subjects: 1691
Study 38837894 — intervention group
Group type: EXPERIMENTAL
Intervention: PIK3CA hotspot mutation p.H1047R
Number of subjects: 1691
Study 38837894 — intervention group
Group type: EXPERIMENTAL
Intervention: Hotspot mutations in exon 9
Number of subjects: 1691
Study 38838026 — intervention group
Group type: EXPERIMENTAL
Intervention: Fedratinib
Number of subjects: 0
Study 38838170 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV)
Number of subjects: 6138
Study 38838170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6138
Study 38838232 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y-aTac-BEAM AHCT
Number of subjects: 20
Study 38838287 — intervention group
Group type: EXPERIMENTAL
Intervention: BEMPEG plus Nivolumab (NIVO)
Number of subjects: 623
Study 38838287 — intervention group
Group type: COMPARATOR
Intervention: Tyrosine kinase inhibitors (TKI; sunitinib or cabozantinib)
Number of subjects: 623
Study 38838311 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab plus ipilimumab
Number of subjects: 115
Study 38838332 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable ring device
Number of subjects: 11
Study 38838332 — intervention group
Group type: EXPERIMENTAL
Intervention: Test device placed on the index finger
Number of subjects: 11
Study 38838332 — intervention group
Group type: EXPERIMENTAL
Intervention: Test device placed on the fingertip
Number of subjects: 11
Study 38838403 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric nursing-led sustainable heat prevention program (3 months duration, includes education on hydration, rest, protective clothing, and recognition of heat-related illnesses)
Number of subjects: 120
Study 38838403 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 120
Study 38838460 — intervention group
Group type: EXPERIMENTAL
Intervention: Access anti-HBc Total assay
Number of subjects: 5983
Study 38838477 — intervention group
Group type: EXPERIMENTAL
Intervention: Phoenix App Only
Number of subjects: 152
Study 38838477 — intervention group
Group type: EXPERIMENTAL
Intervention: Phoenix App + Nicotine Replacement Therapy
Number of subjects: 152
Study 38838477 — intervention group
Group type: COMPARATOR
Intervention: Factoid (Control)
Number of subjects: 152
Study 38838500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemigatinib 13.5 mg once daily in 21-day cycles (2 weeks on, 1 week off) until disease progression or unacceptable toxicity.
Number of subjects: 147
Study 38838501 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab ± ipilimumab combined with stereotactic radiation therapy
Number of subjects: 78
Study 38838501 — intervention group
Group type: COMPARATOR
Intervention: First-line chemotherapy
Number of subjects: 78
Study 38838608 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-free anesthesia (OFA) with dexmedetomidine and lidocaine
Number of subjects: 120
Study 38838608 — intervention group
Group type: COMPARATOR
Intervention: Opioid-based anesthesia (OA) with remifentanil
Number of subjects: 120
Study 38838608 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-free anesthesia (OFA)
Number of subjects: 120
Study 38838985 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum planning intervention
Number of subjects: 320
Study 38838985 — intervention group
Group type: COMPARATOR
Intervention: Standard prenatal care
Number of subjects: 320
Study 38839047 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous remdesivir
Number of subjects: 53
Study 38839101 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer comparison antibiotic prescribing feedback (intervention group)
Number of subjects: 5046
Study 38839101 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 5046
Study 38839101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (overall)
Number of subjects: 5046
Study 38839101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (unnecessary prescribing)
Number of subjects: 5046
Study 38839101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (prolonged duration prescriptions)
Number of subjects: 5046
Study 38839101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (broad spectrum prescribing)
Number of subjects: 5046
Study 38839101 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-mix adjusted reports
Number of subjects: 5046
Study 38839101 — intervention group
Group type: EXPERIMENTAL
Intervention: Emphasis on harms messaging
Number of subjects: 5046
Study 38839252 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin use
Number of subjects: 346
Study 38839252 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of metformin use
Number of subjects: 346
Study 38839251 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified CycleGAN (Digital ray)
Number of subjects: 959
Study 38839251 — intervention group
Group type: COMPARATOR
Intervention: Original CycleGAN
Number of subjects: 959
Study 38839269 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed outreach plus patient navigation
Number of subjects: 2872
Study 38839269 — intervention group
Group type: COMPARATOR
Intervention: Usual care with visit-based screening
Number of subjects: 2872
Study 38839381 — intervention group
Group type: EXPERIMENTAL
Intervention: TROD Screen questionnaire for HIV infection
Number of subjects: 15343
Study 38839381 — intervention group
Group type: EXPERIMENTAL
Intervention: TROD Screen questionnaire for HBV infection in men
Number of subjects: 15343
Study 38839381 — intervention group
Group type: EXPERIMENTAL
Intervention: TROD Screen questionnaire for HBV infection in women
Number of subjects: 15343
Study 38839381 — intervention group
Group type: EXPERIMENTAL
Intervention: TROD Screen questionnaire for HCV infection
Number of subjects: 15343
Study 38839388 — intervention group
Group type: EXPERIMENTAL
Intervention: IOP-lowering eyedrops (intervention group)
Number of subjects: 152
Study 38839388 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 152
Study 38839392 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive counselling package (arm 2)
Number of subjects: 7920
Study 38839392 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive counselling package combined with wider methods availability (arm 3)
Number of subjects: 7920
Study 38839392 — intervention group
Group type: COMPARATOR
Intervention: Routine care (arm 1)
Number of subjects: 7920
Study 38839505 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg every 3 weeks until disease progression or unacceptable toxicity
Number of subjects: 1004
Study 38839899 — intervention group
Group type: EXPERIMENTAL
Intervention: Dazodalibep (DAZ)
Number of subjects: 183
Study 38840084 — intervention group
Group type: EXPERIMENTAL
Intervention: MyBack programme
Number of subjects: 0
Study 38840084 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 38840086 — intervention group
Group type: COMPARATOR
Intervention: Standard CDC information about HPV vaccination (Control)
Number of subjects: 1200
Study 38840086 — intervention group
Group type: EXPERIMENTAL
Intervention: Video narratives about HPV vaccination
Number of subjects: 1200
Study 38840086 — intervention group
Group type: EXPERIMENTAL
Intervention: Written narratives about HPV vaccination
Number of subjects: 1200
Study 38840086 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced access to HPV vaccine + Standard CDC information
Number of subjects: 1200
Study 38840086 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced access to HPV vaccine + Video narratives
Number of subjects: 1200
Study 38840086 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced access to HPV vaccine + Written narratives
Number of subjects: 1200
Study 38840160 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative decision skills training (CDST)
Number of subjects: 0
Study 38840160 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 0
Study 38840166 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline CRP (>3 mg/L)
Number of subjects: 200
Study 38840166 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline IL-6
Number of subjects: 200
Study 38840210 — intervention group
Group type: EXPERIMENTAL
Intervention: Low inhaled concentration of desflurane (0.5 MAC) combined with propofol and remifentanil
Number of subjects: 70
Study 38840210 — intervention group
Group type: COMPARATOR
Intervention: High inhaled concentration of desflurane (0.7-1.0 MAC) combined with remifentanil
Number of subjects: 70
Study 38840219 — intervention group
Group type: EXPERIMENTAL
Intervention: JAK inhibitors (baricitinib, n=15; tofacitinib, n=10; upadacitinib, n=10)
Number of subjects: 35
Study 38840410 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 195
Study 38840410 — intervention group
Group type: COMPARATOR
Intervention: cIVF
Number of subjects: 195
Study 38840578 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperaemic stenosis resistance (HSR) index
Number of subjects: 853
Study 38840580 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of OCT vulnerability features (OCT-VFs) including TCFA, r-MLA, HP, and CP
Number of subjects: 491
Study 38840580 — intervention group
Group type: EXPERIMENTAL
Intervention: TCFA alone
Number of subjects: 491
Study 38840580 — intervention group
Group type: EXPERIMENTAL
Intervention: Coexistence of TCFA with other OCT-VFs
Number of subjects: 491
Study 38840973 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) protocol
Number of subjects: 0
Study 38841077 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture intervention
Number of subjects: 79
Study 38841123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO-OP) intervention
Number of subjects: 0
Study 38841377 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported methods (SRMs) including Morisky-Green test (MGT) and Batalla test (BT)
Number of subjects: 387
Study 38841377 — intervention group
Group type: COMPARATOR
Intervention: Reference method (RM) - pill count
Number of subjects: 387
Study 38841588 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (MACT)
Number of subjects: 0
Study 38841588 — intervention group
Group type: COMPARATOR
Intervention: DAPT (Dual Antiplatelet Therapy)
Number of subjects: 0
Study 38841694 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical stem cell transplantation (HISCT)
Number of subjects: 19
Study 38841781 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1000 mg twice daily on D1-D10 + Etoposide 200 mg on D2-D8
Number of subjects: 11
Study 38841781 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg twice daily on D1-D10 + Etoposide 200 mg on D2-D8
Number of subjects: 11
Study 38841799 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline post-bronchodilator (post-BD) spirometry measures of lung function
Number of subjects: 11181
Study 38841799 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD only
Number of subjects: 11181
Study 38841854 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 2895
Study 38841854 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 2895
Study 38841856 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity statin therapy
Number of subjects: 0
Study 38842053 — intervention group
Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 72
Study 38842053 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG plus MMC
Number of subjects: 72
Study 38842100 — intervention group
Group type: EXPERIMENTAL
Intervention: High VPA (≥1 session/week)
Number of subjects: 0
Study 38842286 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-performed sodium reduction diet
Number of subjects: 72
Study 38842286 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 38842323 — intervention group
Group type: EXPERIMENTAL
Intervention: BPaL (bedaquiline, pretomanid, and linezolid)
Number of subjects: 0
Study 38842323 — intervention group
Group type: EXPERIMENTAL
Intervention: BPaLC (BPaL with clofazimine)
Number of subjects: 0
Study 38842323 — intervention group
Group type: EXPERIMENTAL
Intervention: BPaLM (BPaL with moxifloxacin)
Number of subjects: 0
Study 38842323 — intervention group
Group type: COMPARATOR
Intervention: Age, body mass index, and country
Number of subjects: 0
Study 38842347 — intervention group
Group type: EXPERIMENTAL
Intervention: CLN-617 (intratumoral injection of a single-chain fusion protein comprising IL2 and IL12)
Number of subjects: 0
Study 38842347 — intervention group
Group type: EXPERIMENTAL
Intervention: CLN-617
Number of subjects: 0
Study 38842448 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose DOAC
Number of subjects: 1657
Study 38842448 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose DOAC
Number of subjects: 1657
Study 38842448 — intervention group
Group type: EXPERIMENTAL
Intervention: High C-trough standardized values (>0.50)
Number of subjects: 1657
Study 38842448 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower C-trough standardized values (≤0.50)
Number of subjects: 1657
Study 38842448 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose DOAC use
Number of subjects: 1657
Study 38842520 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa-2a alone (180 μg per week for 48 weeks)
Number of subjects: 174
Study 38842520 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg bulevirtide plus peginterferon alfa-2a (180 μg per week for 48 weeks)
Number of subjects: 174
Study 38842520 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bulevirtide plus peginterferon alfa-2a (180 μg per week for 48 weeks)
Number of subjects: 174
Study 38842520 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bulevirtide monotherapy (for 96 weeks)
Number of subjects: 174
Study 38842606 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant-adjuvant anti-PD1 therapy
Number of subjects: 0
Study 38842606 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant anti-PD-1 therapy
Number of subjects: 0
Study 38842606 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored approach to surgery and adjuvant therapy based on response to initial neoadjuvant immunotherapy
Number of subjects: 0
Study 38842738 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied on days 0, 3, 7, and 14 after extraction, repeated biweekly until the end of retraction.
Number of subjects: 36
Study 38842738 — intervention group
Group type: COMPARATOR
Intervention: Nonlaser group (NLG) without LLLT application.
Number of subjects: 36
Study 38842764 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen 25 mg/vitamin B (thiamine 100 mg, pyridoxine 50 mg, cyanocobalamin 0.50 mg) in a fixed-dose combination (FDC)
Number of subjects: 0
Study 38842764 — intervention group
Group type: COMPARATOR
Intervention: Dexketoprofen 25 mg monotherapy
Number of subjects: 0
Study 38842764 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC of dexketoprofen/thiamine + pyridoxine + cyanocobalamin vitamins
Number of subjects: 0
Study 38842764 — intervention group
Group type: COMPARATOR
Intervention: Dexketoprofen monotherapy
Number of subjects: 0
Study 38842799 — intervention group
Group type: EXPERIMENTAL
Intervention: NCM plus HBPTM (20 counseling calls over 12 months); n=224
Number of subjects: 450
Study 38842799 — intervention group
Group type: COMPARATOR
Intervention: HBPTM alone (12 home BP measurements/week for 12 months); n=226
Number of subjects: 450
Study 38842799 — intervention group
Group type: EXPERIMENTAL
Intervention: NCM plus HBPTM
Number of subjects: 450
Study 38842799 — intervention group
Group type: COMPARATOR
Intervention: HBPTM alone
Number of subjects: 450
Study 38842838 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab plus chemotherapy (nab-paclitaxel and carboplatin) followed by response-adapted locoregional therapy (LRT)
Number of subjects: 77
Study 38842838 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-adapted therapy (group A: single-modality radiotherapy or transoral robotic surgery; group B: intermediate-dose chemoradiotherapy; group C: regular-dose chemoradiotherapy)
Number of subjects: 77
Study 38842838 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery
Number of subjects: 77
Study 38842838 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab and chemotherapy followed by response-adapted LRT
Number of subjects: 77
Study 38842838 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 77
Study 38842850 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (cognitive behavior therapy for psychosis strategies)
Number of subjects: 42
Study 38842850 — intervention group
Group type: COMPARATOR
Intervention: Comparison app (mobile assessment plus psychoeducation)
Number of subjects: 42
Study 38842850 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (mHealth intervention and comparison app)
Number of subjects: 42
Study 38842930 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention (web-delivered PA intervention with text messages and additional features)
Number of subjects: 195
Study 38842930 — intervention group
Group type: COMPARATOR
Intervention: Original intervention (Spanish-language, individually tailored, web-delivered PA intervention)
Number of subjects: 195
Study 38842930 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention for low-active participants
Number of subjects: 195
Study 38842930 — intervention group
Group type: COMPARATOR
Intervention: Original intervention for low-active participants
Number of subjects: 195
Study 38842930 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention for inactive participants
Number of subjects: 195
Study 38842930 — intervention group
Group type: COMPARATOR
Intervention: Original intervention for inactive participants
Number of subjects: 195
Study 38842955 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM) therapy
Number of subjects: 85
Study 38842956 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent TBS (iTBS)
Number of subjects: 15
Study 38842956 — intervention group
Group type: COMPARATOR
Intervention: continuous TBS (cTBS)
Number of subjects: 15
Study 38842956 — intervention group
Group type: COMPARATOR
Intervention: active control cTBS
Number of subjects: 15
Study 38842957 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 13492
Study 38842972 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI + EGF-guided ablation
Number of subjects: 85
Study 38842972 — intervention group
Group type: COMPARATOR
Intervention: PVI only
Number of subjects: 85
Study 38842991 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided DCB angioplasty
Number of subjects: 260
Study 38842991 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided DCB angioplasty
Number of subjects: 260
Study 38843038 — intervention group
Group type: EXPERIMENTAL
Intervention: Clusters based on within-treatment symptom trajectories
Number of subjects: 0
Study 38843105 — intervention group
Group type: EXPERIMENTAL
Intervention: Bexotegrast, dosage and duration not available
Number of subjects: 0
Study 38843105 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 38843149 — intervention group
Group type: EXPERIMENTAL
Intervention: mISP combined with MINDBODYSTRONG© program
Number of subjects: 364
Study 38843149 — intervention group
Group type: COMPARATOR
Intervention: mISP alone
Number of subjects: 364
Study 38843234 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (150 minutes per week at moderate-to-vigorous intensity for 28 weeks)
Number of subjects: 34
Study 38843267 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 μg H1N1 influenza vaccine
Number of subjects: 45
Study 38843267 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 μg H1N1 influenza vaccine
Number of subjects: 45
Study 38843267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 38843267 — intervention group
Group type: EXPERIMENTAL
Intervention: Both VX-103 dose groups
Number of subjects: 45